Edition:
India

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

25.54USD
11:13pm IST
Change (% chg)

$-0.32 (-1.24%)
Prev Close
$25.86
Open
$25.93
Day's High
$25.93
Day's Low
$25.45
Volume
26,920
Avg. Vol
133,233
52-wk High
$41.59
52-wk Low
$18.00

Summary

Name Age Since Current Position

Matthew Patterson

47 2018 Chairman of the Board, Chief Executive Officer

Natalie Holles

46 2018 President, Chief Operating Officer

Thomas Schuetz

58 2013 Co-Founder, Independent Director

Thomas Soloway

52 2019 Chief Financial Officer, Executive Vice President

Mark Meltz

45 2019 Senior Vice President, General Counsel

David Nagler

66 2015 Senior Vice President - Human Resources and Corporate Affairs

Edward Conner

45 2019 Senior Vice President and Chief Medical Officer

Fulvio Mavilio

2019 Senior Vice President - Translational Science

Eric Mosbrooker

52 2019 Senior Vice President and Chief Commercial Officer

Mary Newman

59 2014 Senior Vice President - Regulatory Affairs

Sarah Spencer

2019 Vice President, Corporate Communications

Louis Lange

70 2018 Lead Independent Director

Mark Goldberg

64 2017 Independent Director

Jennifer Jarrett

48 2017 Independent Director

Scott Morrison

61 2015 Independent Director

Julie Smith

48 2016 Independent Director

Andrew Chang

Director, Investor Relations

Biographies

Name Description

Matthew Patterson

Mr. Matthew R. Patterson is Chairman of the Board, Chief Executive Officer of the Company. Prior to Audentes, Mr. Patterson was an Entrepreneur-In-Residence at OrbiMed, and previously worked at Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Genzyme Corporation. Mr. Patterson currently serves as Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He is a member of the Board of Directors for Homology Medicines, Inc. and Modis Therapeutics, Inc. Mr. Patterson received his B.A. in Biochemistry from Bowdoin College. Our board of directors believes that Mr. Patterson should serve as a director due to the perspective he brings as our founder and his expertise in the fields of business, biotechnology and drug development.

Natalie Holles

Ms. Natalie C. Holles is President, Chief Operating Officer of the AUDENTES THERAPEUTICS, INC. She previously served as our Senior Vice President, Chief Operating Officer since August 2015. Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen in 2012, and previously held corporate development and commercial roles at InterMune, Inc. and Genentech, Inc. Ms. Holles holds an A.B. from Stanford University and an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow.

Thomas Schuetz

Dr. Thomas J. Schuetz serves as Co-Founder, Independent Director of the AUDENTES THERAPEUTICS, INC. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC, a biotechnology company, where he has worked since July 2014. Previously, Dr. Schuetz was a consultant in the biotechnology industry from May 2012 to June 2014, including a consultant for us from July 2012 to June 2013. Prior to consulting, Dr. Schuetz was a venture partner at OrbiMed, a healthcare investment firm, where he worked from November 2007 to May 2012. Dr. Schuetz has also served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz previously served on the board of directors of Relypsa, Inc. Dr. Schuetz holds a B.S. from Xavier University, an M.D. from Harvard Medical School and a Ph.D. from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology. Our board of directors believes that Dr. Schuetz’s clinical and executive experience and medical background qualify him to serve on our board of directors.

Thomas Soloway

Mr. Thomas P. Soloway is Chief Financial Officer, Executive Vice President of the Company. He previously served as our Senior Vice President from October 2015 to February 2019. Prior to joining us, Mr. Soloway served as the Senior Vice President and Chief Financial Officer of Ascendis Pharma A/S from January 2014 until September 2015. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc., a biotechnology company, in 2002. At Transcept, Mr. Soloway held various positions, including Chief Financial Officer and Executive Vice President, Chief Operating Officer. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners. Mr. Soloway holds a B.S. from the University of Southern California and an M.B.A. from Georgetown University.

Mark Meltz

Mr. Mark A. Meltz is Senior Vice President, General Counsel of the Company. Prior to joining us, Mr. Meltz worked at PaxVax, Inc., a specialty vaccines company, where he served as Executive Vice President and Chief Business Development and Legal Officer from January 2017 to March 2019 and Executive Vice President and Chief Legal Officer from June 2014 to January 2017. From April 2012 to June 2014, Mr. Meltz served in numerous roles in the Legal Department of Biogen Idec (now Biogen), a neuroscience biotechnology company, including as the lead Lawyer for the Global Medical Affairs Group and as the lead U.S. Commercial Lawyer for Tecfidera® and Tysabri®. Earlier in his career, Mr. Meltz served as the Head of Legal for the North America and Americas Regions at Novartis Vaccines and practiced law at the international law firm Bingham McCutchen LLP (now part of Morgan Lewis & Bockius LLP). Mr. Meltz earned his Juris Doctor from Boston College Law School, Magna Cum Laude, and his B.A. with Departmental Honors in Psychology from Yale University.

David Nagler

Mr. David Nagler was Senior Vice President - Human Resources and Corporate Affairs of the AUDENTES THERAPEUTICS, INC.Prior to joining us, he served as a human resources and corporate development consultant from April 2013 to February 2015. From July 2003 to March 2013, Mr. Nagler served as the Vice President Corporate Affairs at ARYx Therapeutics, Inc., a biotechnology company. He has also served as the Vice President Human Resources at Genentech, Inc. Mr. Nagler has served on the board of directors of U.C. Davis CONNECT, as well as the boards of the Northern California Chapter of the American Liver Foundation and the John Vasconcellos Legacy Project. Mr. Nagler studied at the University of California, Berkeley.

Edward Conner

Mr. Edward R. Conner has been appointed Senior Vice President and Chief Medical Officer of the Company, effective July 15, 2019. Ed joins Audentes from Sangamo Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company's pipeline of genomic therapies. Prior to Sangamo, Ed served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc., where he led the global clinical development efforts for two of the company's rare disease product candidates. Prior to Ultragenyx, Ed served as Senior Medical Director at BioMarin Pharmaceutical Inc., where he led clinical development and regulatory interactions for its global Phase 3 program in Pompe disease, and earlier in his career Ed served as Medical Director at Genentech, Inc. where he was the clinical science team leader of two product candidates, including XOLAIR®. Ed completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco .

Fulvio Mavilio

Mr. Fulvio Mavilio is Senior Vice President - Translational Science of the Company. Fulvio is a highly regarded, world-leading expert and pioneer in the gene therapy field. He has designed and developed gene therapies for inherited and acquired diseases, including the first ever commercially approved ex vivo gene therapy, Strimvelis ® . Fulvio joined Audentes in 2017 from Genethon where he served as Chief Scientific Officer and led the development of a robust pipeline of gene therapy programs, including the initial discovery work for AT132. Prior to Genethon, Fulvio was co-Director of the Center for Regenerative Medicine of the University of Modena, Director of Discovery of Molmed SpA, founder and Chief Scientific Officer of Genera SpA, and co-Director of the San Raffaele-Telethon Institute of Gene Therapy. Fulvio serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia. He earned an undergraduate degree in Biology at the University of Rome and a Ph.D. in Medical Genetics at the University of Rome School of Medicine.

Eric Mosbrooker

Mr. Eric B. Mosbrooker is Senior Vice President and Chief Commercial Officer of the Company. Mr. Mosbrooker served first as Chief Commercial Officer and later as Chief Operating Officer at Origin Biosciences, a subsidiary of BridgeBio Pharma LLC focused on developing a rare pediatric metabolic disorder treatment. From November 2016 to April 2018, following its acquisition of Raptor Pharmaceuticals Corp, he served at Horizon Pharma plc as Group Vice President and GM and later as Senior Vice President and GM. Prior to the acquisition by Horizon Pharma, Mr. Mosbrooker served in various positions at Raptor Pharmaceuticals from November 2012, including Senior Vice President of Americas & Asia Pacific from March 2016 to November 2016. Prior to Raptor, Mr. Mosbrooker served as commercial operations and market access lead for STRENSIQ® at Alexion and Enobia Pharma, Inc. He has held various commercial operational roles at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc., Chiron Corporation (now Novartis) and Millennium Pharmaceuticals. He has experience in management, healthcare and technology consulting at IBM, Teltech Resource Network Corporation and Kohler Company. Mr. Mosbrooker earned his B.S. in industrial engineering from the University of Wisconsin, Madison.

Mary Newman

Ms. Mary Newman is Senior Vice President - Regulatory Affairs of the AUDENTES THERAPEUTICS, INC. Prior to joining Audentes, Ms. Newman served as the Senior Vice President, Regulatory Affairs and Quality Assurance at SARcode Bioscience Inc., which was acquired by Shire Ltd. She previously held various management positions, with increasing responsibility in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc. (now Bayer HealthCare Pharmaceuticals Inc.), and Sequus Pharmaceuticals, Inc. (now Johnson & Johnson). While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan® for the treatment of phenylketonuria (PKU), Naglazyme® for mucopolysaccharidosis (MPS) VI, and supported the final approval of Aldurazyme® for MPS I. She has also held various research and development leadership roles in oncology, neurology, and antifungal therapeutic areas. Ms. Newman holds a B.S. in Physiology from Oregon State University.

Sarah Spencer

Ms. Sarah Spencer is Vice President, Corporate Communications of the company. Sarah has more than 20 years of experience in healthcare and life sciences communications. She joins Audentes from GlaxoSmithKline (GSK) where she was most recently Head, US Corporate Communications. Sarah spent 13 years at GSK working in a variety of global communications roles both in the UK and the US where she had responsibility for corporate media relations, financial communications, crisis communications, reputation management, and product and pipeline communications. Sarah has worked directly with CEO & C-suite executives extensively. Prior to GSK, Sarah worked at Elan Pharmaceuticals (now Perrigo Company) where she led the launch communications for Tysabri ® and helped to build the profile of the company's neurology pipeline. Sarah also worked at Berry PR, a healthcare public relations agency, where she developed and executed communications strategies and campaigns for small and emerging biotech clients. Sarah began her career at Rite Aid Corporation where she served for eight years as a lead media spokesperson handling numerous high-profile issues and crises. Sarah holds a B.S. in Communications & Psychology from the State University of New York at Buffalo.

Louis Lange

Dr. Louis G. Lange is a Lead Independent Director of the Company. Dr. Lange is currently a general partner at Asset Management Ventures, an investment firm, where he has worked since June 2009. Dr. Lange was the co-founder and served as the President and Chief Executive Officer of Cardiogen Sciences, Inc., a biotechnology company, from April 2014 until it was acquired by us in August 2015. Dr. Lange also co-founded CV Therapeutics, Inc. in 1990 and served as the Chairman, Chief Executive Officer and Chief Scientific Officer until it was acquired by Gilead Sciences, Inc. in 2009. Dr. Lange has also served as the Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University. Dr. Lange served on the board of directors of Maxygen, Inc. from December 2005 to August 2013, CymaBay Therapeutics, Inc. from November 2003 to October 2015, and Esperion Therapeutics, Inc. from February 2010 to May 2014. Dr. Lange also serves as a member of the Board of Trustees at the University of Rochester, The Gladstone Foundation, is a senior advisor to Gilead and was on the board of directors of BIO (the trade organization of biotech companies) from 1998 to 2009, as well as other private companies. Dr. Lange holds a B.A. from the University of Rochester, an M.D. from Harvard Medical School and a Ph.D. from Harvard University. Our board of directors believes that Dr. Lange’s deep experience in molecular cardiology and biotechnology business development qualifies him to serve on our board of directors.

Mark Goldberg

Dr. Mark Goldberg is Independent Director of the Company. since December 2017. Dr. Goldberg holds an A.B. from Harvard College and an M.D. from Harvard Medical School. Our board of directors believes that Dr. Goldberg’s extensive experience in oncology, rare disease and gene therapy development and the biotechnology industry qualifies him to serve on our board of directors. Dr. Goldberg holds an A.B. from Harvard College and an M.D. from Harvard Medical School. Our board of directors believes that Dr. Goldberg’s extensive experience in oncology, rare disease and gene therapy development and the biotechnology industry qualifies him to serve on our board of directors.

Jennifer Jarrett

Ms. Jennifer Jarrett is a directors AUDENTES THERAPEUTICS, INC. Ms. Jarrett currently serves as the Vice President, Corporate Development and Capital Markets of Uber Technologies, Inc. Prior to Uber, Ms. Jarrett served as the Chief Financial and Operating Officer of Arcus Biosciences, Inc., an immunotherapy biopharmaceutical company, since March 2017. Previously, Ms. Jarrett served as Chief Financial Officer of Medivation, Inc., a small molecule biopharmaceutical company, from April 2016 until the company’s purchase by Pfizer, Inc. in September 2016. Prior to Medivation, Ms. Jarrett served as Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for building and managing Citigroup’s West Coast life sciences investment banking practice. Prior to Citigroup, Ms. Jarrett was a Managing Director in Credit Suisse’s Health Care Group focused on the biotechnology sector. Ms. Jarrett also serves on the board of directors of Arcus Biosciences, Inc., Arena Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc. She earned a B.A. in economics, cum laude, from Dartmouth College and holds an M.B.A. from the Stanford Graduate School of Business. Our board of directors believes that Ms. Jarrett should serve as a director due to her extensive experience in the life science industry and financial management of life science companies.

Scott Morrison

Mr. Scott W. Morrison is an Independent Director of the AUDENTES THERAPEUTICS, INC. Mr. Morrison was a partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison has served life sciences companies since 1980. Mr. Morrison serves on the board, chairs the audit committees and is a member of the compensation committees of Global Blood Therapeutics Inc. and Corvus Pharmaceuticals, Inc. Mr. Morrison serves on the board of directors and chairs the audit committees of Ideaya Biosciences, Inc. and Symic Bio. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations, including the Biotechnology Institute, the Life Sciences Foundation, the Bay Area Biosciences Association and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California-Berkeley and is a certified public accountant (inactive). Our board of directors believes that Mr. Morrison’s extensive experience in public accounting and the life sciences industry qualifies him to serve on our board of directors.

Julie Smith

Ms. Julie Smith is an Independent Director of the AUDENTES THERAPEUTICS, INC. Ms. Smith is the President and Chief Executive Officer of E-Scape Bio, Inc., a biotechnology company developing novel small-molecule therapeutics for inherited neurodegenerative diseases. Previously, Ms. Smith served as the President and Chief Executive Officer at Nuredis, Inc., and President and Chief Executive Officer at Raptor Pharmaceutical Corp., a public, commercial stage biopharmaceutical company focused on developing and commercializing treatments for orphan diseases, which she joined in September 2012. Prior to joining Raptor, Ms. Smith served as the Chief Commercial Officer at Enobia Pharmaceuticals until May 2012 after its acquisition by Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals, Genzyme, Novazyme and Bristol-Myers Squibb. Ms. Smith currently serves as an independent director of Exelixis. She previously served as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. Ms. Smith holds a B.S. in Biological and Nutritional Sciences from Cornell University. Our board of directors believes that Ms. Smith’s extensive executive level experience at biotechnology companies qualifies her to serve on our board of directors.

Andrew Chang